Literature DB >> 31563626

Chemoprevention of Colorectal Cancer.

Bryson W Katona1, Jennifer M Weiss2.   

Abstract

Although colorectal cancer (CRC) screening has reduced the incidence of and mortality from CRC, chemoprevention strategies have the potential to further reduce CRC incidence and mortality. Chemoprevention agents might be used for average-risk as well as high-risk groups, and to prevent CRC recurrence after therapy. CRC chemoprevention agents that have been studied include aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, statins, agents that target metabolic pathways, and vitamins and minerals. We review the prospect of chemoprevention of CRC, results from preclinical and human studies, challenges, and future directions.
Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adenoma; Chemoprevention; Colorectal Cancer

Mesh:

Substances:

Year:  2019        PMID: 31563626      PMCID: PMC6981249          DOI: 10.1053/j.gastro.2019.06.047

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  214 in total

1.  Aspirin, Ibuprofen, and the Risk of Colorectal Cancer in Lynch Syndrome.

Authors:  Driss Ait Ouakrim; Seyedeh Ghazaleh Dashti; Rowena Chau; Daniel D Buchanan; Mark Clendenning; Christophe Rosty; Ingrid M Winship; Joanne P Young; Graham G Giles; Barbara Leggett; Finlay A Macrae; Dennis J Ahnen; Graham Casey; Steven Gallinger; Robert W Haile; Loïc Le Marchand; Stephen N Thibodeau; Noralane M Lindor; Polly A Newcomb; John D Potter; John A Baron; John L Hopper; Mark A Jenkins; Aung Ko Win
Journal:  J Natl Cancer Inst       Date:  2015-06-24       Impact factor: 13.506

2.  Calcium, vitamin D, dairy products, and risk of colorectal cancer in the Cancer Prevention Study II Nutrition Cohort (United States).

Authors:  Marjorie L McCullough; Andrea S Robertson; Carmen Rodriguez; Eric J Jacobs; Ann Chao; Jonas Carolyn; Eugenia E Calle; Walter C Willett; Michael J Thun
Journal:  Cancer Causes Control       Date:  2003-02       Impact factor: 2.506

3.  Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial.

Authors:  Nancy R Cook; I-Min Lee; Shumin M Zhang; M Vinayaga Moorthy; Julie E Buring
Journal:  Ann Intern Med       Date:  2013-07-16       Impact factor: 25.391

4.  Randomized double-blind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps.

Authors:  Tetsuji Takayama; Hiroyuki Nagashima; Masahiro Maeda; Shuichi Nojiri; Michiaki Hirayama; Yoichiro Nakano; Yasuo Takahashi; Yasushi Sato; Hitoshi Sekikawa; Mitsuru Mori; Tomoko Sonoda; Tetsuo Kimura; Junji Kato; Yoshiro Niitsu
Journal:  Clin Cancer Res       Date:  2011-03-08       Impact factor: 12.531

5.  A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis.

Authors:  John Burn; D Timothy Bishop; Pamela D Chapman; Faye Elliott; Lucio Bertario; Malcolm G Dunlop; Diana Eccles; Anthony Ellis; D Gareth Evans; Riccardo Fodde; Eamonn R Maher; Gabriela Möslein; Hans F A Vasen; Julie Coaker; Robin K S Phillips; Steffen Bülow; John C Mathers
Journal:  Cancer Prev Res (Phila)       Date:  2011-05

6.  Folate intake and colorectal cancer risk: a meta-analytical approach.

Authors:  Miguel A Sanjoaquin; Naomi Allen; Elisabeth Couto; Andrew W Roddam; Timothy J Key
Journal:  Int J Cancer       Date:  2005-02-20       Impact factor: 7.396

7.  Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis.

Authors:  F M Giardiello; S R Hamilton; A J Krush; S Piantadosi; L M Hylind; P Celano; S V Booker; C R Robinson; G J Offerhaus
Journal:  N Engl J Med       Date:  1993-05-06       Impact factor: 91.245

Review 8.  The role of vitamin D in reducing cancer risk and progression.

Authors:  David Feldman; Aruna V Krishnan; Srilatha Swami; Edward Giovannucci; Brian J Feldman
Journal:  Nat Rev Cancer       Date:  2014-04-04       Impact factor: 60.716

9.  ASPirin Intervention for the REDuction of colorectal cancer risk (ASPIRED): a study protocol for a randomized controlled trial.

Authors:  David A Drew; Samantha M Chin; Katherine K Gilpin; Melanie Parziale; Emily Pond; Madeline M Schuck; Kathleen Stewart; Meaghan Flagg; Crystal A Rawlings; Vadim Backman; Peter J Carolan; Daniel C Chung; Francis P Colizzo; Matthew Freedman; Manish Gala; John J Garber; Curtis Huttenhower; Dmitriy Kedrin; Hamed Khalili; Douglas S Kwon; Sanford D Markowitz; Ginger L Milne; Norman S Nishioka; James M Richter; Hemant K Roy; Kyle Staller; Molin Wang; Andrew T Chan
Journal:  Trials       Date:  2017-02-01       Impact factor: 2.279

10.  Long-term use of metformin and colorectal cancer risk in type II diabetics: a population-based case-control study.

Authors:  Majken Cardel; Sara M Jensen; Anton Pottegård; Trine L Jørgensen; Jesper Hallas
Journal:  Cancer Med       Date:  2014-08-05       Impact factor: 4.452

View more
  42 in total

1.  Curcumin and NCLX inhibitors share anti-tumoral mechanisms in microsatellite-instability-driven colorectal cancer.

Authors:  William Raoul; Thierry Lecomte; Maxime Guéguinou; Sajida Ibrahim; Jérôme Bourgeais; Alison Robert; Trayambak Pathak; Xuexin Zhang; David Crottès; Jacques Dupuy; David Ternant; Valérie Monbet; Roseline Guibon; Hector Flores-Romero; Antoine Lefèvre; Stéphanie Lerondel; Alain Le Pape; Jean-François Dumas; Philippe G Frank; Alban Girault; Romain Chautard; Françoise Guéraud; Ana J García-Sáez; Mehdi Ouaissi; Patrick Emond; Olivier Sire; Olivier Hérault; Gaëlle Fromont-Hankard; Christophe Vandier; David Tougeron; Mohamed Trebak
Journal:  Cell Mol Life Sci       Date:  2022-05-08       Impact factor: 9.261

2.  Role of endoplasmic reticulum stress in apoptosis induced by HK2 inhibitor and its potential as a new drug combination strategy.

Authors:  Jiateng Zhong; Shuya Lu; Xiaoling Jia; Qian Li; Lei Liu; Pei Xie; Guodong Wang; Manman Lu; Wuji Gao; Tiesuo Zhao; Qianqing Wang; Wei Su; Na Li
Journal:  Cell Stress Chaperones       Date:  2022-03-30       Impact factor: 3.827

3.  LncRNA LINC01315 silencing modulates cancer stem cell properties and epithelial-to-mesenchymal transition in colorectal cancer via miR-484/DLK1 axis.

Authors:  Youran Li; Wei Wang; Minna Wu; Ping Zhu; Zailong Zhou; Yuxia Gong; Yunfei Gu
Journal:  Cell Cycle       Date:  2022-02-13       Impact factor: 5.173

4.  Long-Term Statin Use, Total Cholesterol Level, and Risk of Colorectal Cancer: A Prospective Cohort Study.

Authors:  Yin Zhang; Kana Wu; Andrew T Chan; Jeffrey A Meyerhardt; Edward L Giovannucci
Journal:  Am J Gastroenterol       Date:  2022-01-01       Impact factor: 12.045

5.  Long-term Aspirin Use and Epigenetic Mitotic Clocks for Cancer Risk Prediction: Findings in Healthy Colon Mucosa and Recommendations for Future Epigenetic Aging Studies.

Authors:  Jamaji C Nwanaji-Enwerem; Chijioke Nze; Andres Cardenas
Journal:  Epigenetics Commun       Date:  2021-12-20

6.  Colorectal neoplasms in melanosis coli: a survey in Japan and a worldwide meta-analysis.

Authors:  Ryo Katsumata; Noriaki Manabe; Minoru Fujita; Maki Ayaki; Aya Sunago; Tomoari Kamada; Yasumasa Monobe; Hirofumi Kawamoto; Ken Haruma
Journal:  Int J Colorectal Dis       Date:  2021-06-22       Impact factor: 2.571

Review 7.  Metformin, Microbiome and Protection Against Colorectal Cancer.

Authors:  Georgina R Jones; Mark P Molloy
Journal:  Dig Dis Sci       Date:  2020-06-12       Impact factor: 3.199

Review 8.  Aspirin in the Prevention of Colorectal Neoplasia.

Authors:  David A Drew; Andrew T Chan
Journal:  Annu Rev Med       Date:  2020-10-09       Impact factor: 13.739

Review 9.  Evolutionary dynamics in Barrett oesophagus: implications for surveillance, risk stratification and therapy.

Authors:  Melissa Schmidt; Richard J Hackett; Ann-Marie Baker; Stuart A C McDonald; Michael Quante; Trevor A Graham
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-11-02       Impact factor: 46.802

10.  Timing of Aspirin Use in Colorectal Cancer Chemoprevention: A Prospective Cohort Study.

Authors:  Yin Zhang; Andrew T Chan; Jeffrey A Meyerhardt; Edward L Giovannucci
Journal:  J Natl Cancer Inst       Date:  2021-07-01       Impact factor: 11.816

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.